Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

ENTRATA: CB-839 With Everolimus vs. Placebo With Everolimus in Patients With RCC
ENTRATA- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Status: Enrolling
Updated:  12/31/1969
Sarah Cannon Research Institute Tennessee Oncology
mi
from
Nashville, TN
ENTRATA: CB-839 With Everolimus vs. Placebo With Everolimus in Patients With RCC
ENTRATA- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Status: Enrolling
Updated: 12/31/1969
Sarah Cannon Research Institute Tennessee Oncology
mi
from
Nashville, TN
Click here to add this to my saved trials
ENTRATA: CB-839 With Everolimus vs. Placebo With Everolimus in Patients With RCC
ENTRATA- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Status: Enrolling
Updated:  12/31/1969
Florida Cancer Specialists - South
mi
from
Fort Myers, FL
ENTRATA: CB-839 With Everolimus vs. Placebo With Everolimus in Patients With RCC
ENTRATA- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Status: Enrolling
Updated: 12/31/1969
Florida Cancer Specialists - South
mi
from
Fort Myers, FL
Click here to add this to my saved trials
ENTRATA: CB-839 With Everolimus vs. Placebo With Everolimus in Patients With RCC
ENTRATA- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Status: Enrolling
Updated:  12/31/1969
Florida Cancer Specialists North
mi
from
Saint Petersburg, FL
ENTRATA: CB-839 With Everolimus vs. Placebo With Everolimus in Patients With RCC
ENTRATA- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Status: Enrolling
Updated: 12/31/1969
Florida Cancer Specialists North
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials
ENTRATA: CB-839 With Everolimus vs. Placebo With Everolimus in Patients With RCC
ENTRATA- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Status: Enrolling
Updated:  12/31/1969
SUNY Upstate Medical University
mi
from
Syracuse, NY
ENTRATA: CB-839 With Everolimus vs. Placebo With Everolimus in Patients With RCC
ENTRATA- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Status: Enrolling
Updated: 12/31/1969
SUNY Upstate Medical University
mi
from
Syracuse, NY
Click here to add this to my saved trials
ENTRATA: CB-839 With Everolimus vs. Placebo With Everolimus in Patients With RCC
ENTRATA- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Status: Enrolling
Updated:  12/31/1969
Wenatchee Valley Hospital and Clinics
mi
from
Wenatchee, WA
ENTRATA: CB-839 With Everolimus vs. Placebo With Everolimus in Patients With RCC
ENTRATA- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Status: Enrolling
Updated: 12/31/1969
Wenatchee Valley Hospital and Clinics
mi
from
Wenatchee, WA
Click here to add this to my saved trials
ENTRATA: CB-839 With Everolimus vs. Placebo With Everolimus in Patients With RCC
ENTRATA- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Status: Enrolling
Updated:  12/31/1969
University of Wisconsin Carbone Cancer Center
mi
from
Madison, WI
ENTRATA: CB-839 With Everolimus vs. Placebo With Everolimus in Patients With RCC
ENTRATA- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Status: Enrolling
Updated: 12/31/1969
University of Wisconsin Carbone Cancer Center
mi
from
Madison, WI
Click here to add this to my saved trials
ENTRATA: CB-839 With Everolimus vs. Placebo With Everolimus in Patients With RCC
ENTRATA- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Status: Enrolling
Updated:  12/31/1969
Stanford Cancer Center
mi
from
Stanford, CA
ENTRATA: CB-839 With Everolimus vs. Placebo With Everolimus in Patients With RCC
ENTRATA- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Status: Enrolling
Updated: 12/31/1969
Stanford Cancer Center
mi
from
Stanford, CA
Click here to add this to my saved trials
ENTRATA: CB-839 With Everolimus vs. Placebo With Everolimus in Patients With RCC
ENTRATA- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Status: Enrolling
Updated:  12/31/1969
Northwest Georgia Oncology Centers, PC
mi
from
Marietta, GA
ENTRATA: CB-839 With Everolimus vs. Placebo With Everolimus in Patients With RCC
ENTRATA- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Status: Enrolling
Updated: 12/31/1969
Northwest Georgia Oncology Centers, PC
mi
from
Marietta, GA
Click here to add this to my saved trials
ENTRATA: CB-839 With Everolimus vs. Placebo With Everolimus in Patients With RCC
ENTRATA- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Status: Enrolling
Updated:  12/31/1969
Anne Arundel Medical Center Oncology and Hematology
mi
from
Annapolis, MD
ENTRATA: CB-839 With Everolimus vs. Placebo With Everolimus in Patients With RCC
ENTRATA- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Status: Enrolling
Updated: 12/31/1969
Anne Arundel Medical Center Oncology and Hematology
mi
from
Annapolis, MD
Click here to add this to my saved trials
ENTRATA: CB-839 With Everolimus vs. Placebo With Everolimus in Patients With RCC
ENTRATA- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Status: Enrolling
Updated:  12/31/1969
St. Vincent Frontier Cancer Center
mi
from
Billings, MT
ENTRATA: CB-839 With Everolimus vs. Placebo With Everolimus in Patients With RCC
ENTRATA- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Status: Enrolling
Updated: 12/31/1969
St. Vincent Frontier Cancer Center
mi
from
Billings, MT
Click here to add this to my saved trials
ENTRATA: CB-839 With Everolimus vs. Placebo With Everolimus in Patients With RCC
ENTRATA- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Status: Enrolling
Updated:  12/31/1969
Ann B. Barshinger Cancer Institute / Lancaster General Hospital
mi
from
Lancaster, PA
ENTRATA: CB-839 With Everolimus vs. Placebo With Everolimus in Patients With RCC
ENTRATA- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Status: Enrolling
Updated: 12/31/1969
Ann B. Barshinger Cancer Institute / Lancaster General Hospital
mi
from
Lancaster, PA
Click here to add this to my saved trials
ENTRATA: CB-839 With Everolimus vs. Placebo With Everolimus in Patients With RCC
ENTRATA- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Status: Enrolling
Updated:  12/31/1969
UT/Erlanger Oncology & Hematology
mi
from
Chattanooga, TN
ENTRATA: CB-839 With Everolimus vs. Placebo With Everolimus in Patients With RCC
ENTRATA- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Status: Enrolling
Updated: 12/31/1969
UT/Erlanger Oncology & Hematology
mi
from
Chattanooga, TN
Click here to add this to my saved trials
ENTRATA: CB-839 With Everolimus vs. Placebo With Everolimus in Patients With RCC
ENTRATA- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Status: Enrolling
Updated:  12/31/1969
University of Arizona Cancer Center
mi
from
Tucson, AZ
ENTRATA: CB-839 With Everolimus vs. Placebo With Everolimus in Patients With RCC
ENTRATA- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Status: Enrolling
Updated: 12/31/1969
University of Arizona Cancer Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
ENTRATA: CB-839 With Everolimus vs. Placebo With Everolimus in Patients With RCC
ENTRATA- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Status: Enrolling
Updated:  12/31/1969
"UCLA Department of Medicine Hematology/Oncology
mi
from
Los Angeles, CA
ENTRATA: CB-839 With Everolimus vs. Placebo With Everolimus in Patients With RCC
ENTRATA- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Status: Enrolling
Updated: 12/31/1969
"UCLA Department of Medicine Hematology/Oncology
mi
from
Los Angeles, CA
Click here to add this to my saved trials
ENTRATA: CB-839 With Everolimus vs. Placebo With Everolimus in Patients With RCC
ENTRATA- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Status: Enrolling
Updated:  12/31/1969
St Luke's Mountain States Tumor Institute
mi
from
Boise, ID
ENTRATA: CB-839 With Everolimus vs. Placebo With Everolimus in Patients With RCC
ENTRATA- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Status: Enrolling
Updated: 12/31/1969
St Luke's Mountain States Tumor Institute
mi
from
Boise, ID
Click here to add this to my saved trials
ENTRATA: CB-839 With Everolimus vs. Placebo With Everolimus in Patients With RCC
ENTRATA- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Status: Enrolling
Updated:  12/31/1969
Parkview Research Center
mi
from
Fort Wayne, IN
ENTRATA: CB-839 With Everolimus vs. Placebo With Everolimus in Patients With RCC
ENTRATA- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Status: Enrolling
Updated: 12/31/1969
Parkview Research Center
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
ENTRATA: CB-839 With Everolimus vs. Placebo With Everolimus in Patients With RCC
ENTRATA- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Status: Enrolling
Updated:  12/31/1969
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
ENTRATA: CB-839 With Everolimus vs. Placebo With Everolimus in Patients With RCC
ENTRATA- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Status: Enrolling
Updated: 12/31/1969
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
Click here to add this to my saved trials
ENTRATA: CB-839 With Everolimus vs. Placebo With Everolimus in Patients With RCC
ENTRATA- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Status: Enrolling
Updated:  12/31/1969
Norton Cancer Institute - Norton HealthCare Pavilion
mi
from
Louisville, KY
ENTRATA: CB-839 With Everolimus vs. Placebo With Everolimus in Patients With RCC
ENTRATA- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Status: Enrolling
Updated: 12/31/1969
Norton Cancer Institute - Norton HealthCare Pavilion
mi
from
Louisville, KY
Click here to add this to my saved trials
ENTRATA: CB-839 With Everolimus vs. Placebo With Everolimus in Patients With RCC
ENTRATA- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Status: Enrolling
Updated:  12/31/1969
Ochsner Clinical Foundation
mi
from
New Orleans, LA
ENTRATA: CB-839 With Everolimus vs. Placebo With Everolimus in Patients With RCC
ENTRATA- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Status: Enrolling
Updated: 12/31/1969
Ochsner Clinical Foundation
mi
from
New Orleans, LA
Click here to add this to my saved trials
ENTRATA: CB-839 With Everolimus vs. Placebo With Everolimus in Patients With RCC
ENTRATA- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Status: Enrolling
Updated:  12/31/1969
University of Maryland Greenebaum Comprehensive Cancer Center
mi
from
Baltimore, MD
ENTRATA: CB-839 With Everolimus vs. Placebo With Everolimus in Patients With RCC
ENTRATA- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Status: Enrolling
Updated: 12/31/1969
University of Maryland Greenebaum Comprehensive Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
ENTRATA: CB-839 With Everolimus vs. Placebo With Everolimus in Patients With RCC
ENTRATA- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Status: Enrolling
Updated:  12/31/1969
Metro Minnesota Community Oncology Research Consortium
mi
from
Saint Louis Park, MN
ENTRATA: CB-839 With Everolimus vs. Placebo With Everolimus in Patients With RCC
ENTRATA- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Status: Enrolling
Updated: 12/31/1969
Metro Minnesota Community Oncology Research Consortium
mi
from
Saint Louis Park, MN
Click here to add this to my saved trials
ENTRATA: CB-839 With Everolimus vs. Placebo With Everolimus in Patients With RCC
ENTRATA- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
ENTRATA: CB-839 With Everolimus vs. Placebo With Everolimus in Patients With RCC
ENTRATA- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
ENTRATA: CB-839 With Everolimus vs. Placebo With Everolimus in Patients With RCC
ENTRATA- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Status: Enrolling
Updated:  12/31/1969
Comprehensive Cancer Centers of Nevada
mi
from
Las Vegas, NV
ENTRATA: CB-839 With Everolimus vs. Placebo With Everolimus in Patients With RCC
ENTRATA- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Status: Enrolling
Updated: 12/31/1969
Comprehensive Cancer Centers of Nevada
mi
from
Las Vegas, NV
Click here to add this to my saved trials
ENTRATA: CB-839 With Everolimus vs. Placebo With Everolimus in Patients With RCC
ENTRATA- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Status: Enrolling
Updated:  12/31/1969
Montefiore Medical Center
mi
from
Bronx, NY
ENTRATA: CB-839 With Everolimus vs. Placebo With Everolimus in Patients With RCC
ENTRATA- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Status: Enrolling
Updated: 12/31/1969
Montefiore Medical Center
mi
from
Bronx, NY
Click here to add this to my saved trials
ENTRATA: CB-839 With Everolimus vs. Placebo With Everolimus in Patients With RCC
ENTRATA- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
ENTRATA: CB-839 With Everolimus vs. Placebo With Everolimus in Patients With RCC
ENTRATA- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
ENTRATA: CB-839 With Everolimus vs. Placebo With Everolimus in Patients With RCC
ENTRATA- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Status: Enrolling
Updated:  12/31/1969
University of Cincinnati Medical Center
mi
from
Cincinnati, OH
ENTRATA: CB-839 With Everolimus vs. Placebo With Everolimus in Patients With RCC
ENTRATA- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Status: Enrolling
Updated: 12/31/1969
University of Cincinnati Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
ENTRATA: CB-839 With Everolimus vs. Placebo With Everolimus in Patients With RCC
ENTRATA- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Status: Enrolling
Updated:  12/31/1969
Utah Cancer Specialists
mi
from
Salt Lake City, UT
ENTRATA: CB-839 With Everolimus vs. Placebo With Everolimus in Patients With RCC
ENTRATA- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Status: Enrolling
Updated: 12/31/1969
Utah Cancer Specialists
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
ENTRATA: CB-839 With Everolimus vs. Placebo With Everolimus in Patients With RCC
ENTRATA- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Status: Enrolling
Updated:  12/31/1969
Los Angeles Hematology/Oncology Medical Group
mi
from
Los Angeles, CA
ENTRATA: CB-839 With Everolimus vs. Placebo With Everolimus in Patients With RCC
ENTRATA- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Status: Enrolling
Updated: 12/31/1969
Los Angeles Hematology/Oncology Medical Group
mi
from
Los Angeles, CA
Click here to add this to my saved trials
ENTRATA: CB-839 With Everolimus vs. Placebo With Everolimus in Patients With RCC
ENTRATA- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Status: Enrolling
Updated:  12/31/1969
SCRI HCA Midwest
mi
from
Kansas City, MO
ENTRATA: CB-839 With Everolimus vs. Placebo With Everolimus in Patients With RCC
ENTRATA- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Status: Enrolling
Updated: 12/31/1969
SCRI HCA Midwest
mi
from
Kansas City, MO
Click here to add this to my saved trials
ENTRATA: CB-839 With Everolimus vs. Placebo With Everolimus in Patients With RCC
ENTRATA- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Status: Enrolling
Updated:  12/31/1969
Monongahela Valley Hospital
mi
from
Monongahela, PA
ENTRATA: CB-839 With Everolimus vs. Placebo With Everolimus in Patients With RCC
ENTRATA- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Status: Enrolling
Updated: 12/31/1969
Monongahela Valley Hospital
mi
from
Monongahela, PA
Click here to add this to my saved trials
ENTRATA: CB-839 With Everolimus vs. Placebo With Everolimus in Patients With RCC
ENTRATA- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
ENTRATA: CB-839 With Everolimus vs. Placebo With Everolimus in Patients With RCC
ENTRATA- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
ENTRATA: CB-839 With Everolimus vs. Placebo With Everolimus in Patients With RCC
ENTRATA- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Status: Enrolling
Updated:  12/31/1969
Northwestern University
mi
from
Chicago, IL
ENTRATA: CB-839 With Everolimus vs. Placebo With Everolimus in Patients With RCC
ENTRATA- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Status: Enrolling
Updated: 12/31/1969
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
ENTRATA: CB-839 With Everolimus vs. Placebo With Everolimus in Patients With RCC
ENTRATA- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Status: Enrolling
Updated:  12/31/1969
Mercy Clinic Oncology & Hematology
mi
from
Joplin, MO
ENTRATA: CB-839 With Everolimus vs. Placebo With Everolimus in Patients With RCC
ENTRATA- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Status: Enrolling
Updated: 12/31/1969
Mercy Clinic Oncology & Hematology
mi
from
Joplin, MO
Click here to add this to my saved trials
ENTRATA: CB-839 With Everolimus vs. Placebo With Everolimus in Patients With RCC
ENTRATA- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Status: Enrolling
Updated:  12/31/1969
North Shore Hematology Oncology Associates PC DBA NY Cancer and Blood Specialists
mi
from
East Setauket, NY
ENTRATA: CB-839 With Everolimus vs. Placebo With Everolimus in Patients With RCC
ENTRATA- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Status: Enrolling
Updated: 12/31/1969
North Shore Hematology Oncology Associates PC DBA NY Cancer and Blood Specialists
mi
from
East Setauket, NY
Click here to add this to my saved trials
ENTRATA: CB-839 With Everolimus vs. Placebo With Everolimus in Patients With RCC
ENTRATA- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Status: Enrolling
Updated:  12/31/1969
NYU Winthrop Hospital - Cancer Clinical Trials Oncology/Hematology
mi
from
Mineola, NY
ENTRATA: CB-839 With Everolimus vs. Placebo With Everolimus in Patients With RCC
ENTRATA- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Status: Enrolling
Updated: 12/31/1969
NYU Winthrop Hospital - Cancer Clinical Trials Oncology/Hematology
mi
from
Mineola, NY
Click here to add this to my saved trials
Scale Down for Endometrial Cancer
Scale Down: A Randomized, Controlled Weight Management Intervention for Women With Endometrial Cancer
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Scale Down for Endometrial Cancer
Scale Down: A Randomized, Controlled Weight Management Intervention for Women With Endometrial Cancer
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Study of Stepped Palliative Care in Patients With Advanced Lung Cancer DF/HCC SOCIAL-BEHAVIORAL RESERACH PROTOCOL
Pilot Study of Stepped Palliative Care in Patients With Advanced Lung Cancer DF/HCC SOCIAL-BEHAVIORAL RESERACH PROTOCOL
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Study of Stepped Palliative Care in Patients With Advanced Lung Cancer DF/HCC SOCIAL-BEHAVIORAL RESERACH PROTOCOL
Pilot Study of Stepped Palliative Care in Patients With Advanced Lung Cancer DF/HCC SOCIAL-BEHAVIORAL RESERACH PROTOCOL
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Dose Escalated Proton Beam Therapy or Photon Therapy for Esophageal Cancer
A Phase II Trial of Dose Escalated Proton Beam Therapy or Photon Therapy for Resectable and Unresectable Esophageal Cancer
Status: Enrolling
Updated:  12/31/1969
University of Florida Proton Therapy Institute
mi
from
Jacksonville, FL
Dose Escalated Proton Beam Therapy or Photon Therapy for Esophageal Cancer
A Phase II Trial of Dose Escalated Proton Beam Therapy or Photon Therapy for Resectable and Unresectable Esophageal Cancer
Status: Enrolling
Updated: 12/31/1969
University of Florida Proton Therapy Institute
mi
from
Jacksonville, FL
Click here to add this to my saved trials
High Physical Activity During a Weight Loss Intervention for Breast Cancer Survivors and High Risk Women
High Energy Expenditure From Physical Activity During a Weight Loss Intervention for Breast Cancer Survivors and High Risk Women
Status: Enrolling
Updated:  12/31/1969
University of Kansas Medical Center
mi
from
Kansas City, KA
High Physical Activity During a Weight Loss Intervention for Breast Cancer Survivors and High Risk Women
High Energy Expenditure From Physical Activity During a Weight Loss Intervention for Breast Cancer Survivors and High Risk Women
Status: Enrolling
Updated: 12/31/1969
University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
Evaluate the Effect of Entrectinib on the Pharmacokinetics of Midazolam in Cancer Patients
A Phase 1 Study to Evaluate the Potential Pharmacokinetic Interaction Between Entrectinib and Midazolam in Cancer Patients
Status: Enrolling
Updated:  12/31/1969
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Evaluate the Effect of Entrectinib on the Pharmacokinetics of Midazolam in Cancer Patients
A Phase 1 Study to Evaluate the Potential Pharmacokinetic Interaction Between Entrectinib and Midazolam in Cancer Patients
Status: Enrolling
Updated: 12/31/1969
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Click here to add this to my saved trials
Evaluate the Effect of Entrectinib on the Pharmacokinetics of Midazolam in Cancer Patients
A Phase 1 Study to Evaluate the Potential Pharmacokinetic Interaction Between Entrectinib and Midazolam in Cancer Patients
Status: Enrolling
Updated:  12/31/1969
SCRI-Denver Drug Development Program
mi
from
Denver, CO
Evaluate the Effect of Entrectinib on the Pharmacokinetics of Midazolam in Cancer Patients
A Phase 1 Study to Evaluate the Potential Pharmacokinetic Interaction Between Entrectinib and Midazolam in Cancer Patients
Status: Enrolling
Updated: 12/31/1969
SCRI-Denver Drug Development Program
mi
from
Denver, CO
Click here to add this to my saved trials
Evaluate the Effect of Entrectinib on the Pharmacokinetics of Midazolam in Cancer Patients
A Phase 1 Study to Evaluate the Potential Pharmacokinetic Interaction Between Entrectinib and Midazolam in Cancer Patients
Status: Enrolling
Updated:  12/31/1969
Florida Cancer Specialists - Sarasota (North Catttlemen Rd)
mi
from
Sarasota, FL
Evaluate the Effect of Entrectinib on the Pharmacokinetics of Midazolam in Cancer Patients
A Phase 1 Study to Evaluate the Potential Pharmacokinetic Interaction Between Entrectinib and Midazolam in Cancer Patients
Status: Enrolling
Updated: 12/31/1969
Florida Cancer Specialists - Sarasota (North Catttlemen Rd)
mi
from
Sarasota, FL
Click here to add this to my saved trials
Using Virtual Reality (VR) Models for Preoperative Planning
Using Virtual Reality (VR) Models for Preoperative Planning
Status: Enrolling
Updated:  12/31/1969
Swedish Urology Group
mi
from
Seattle, WA
Using Virtual Reality (VR) Models for Preoperative Planning
Using Virtual Reality (VR) Models for Preoperative Planning
Status: Enrolling
Updated: 12/31/1969
Swedish Urology Group
mi
from
Seattle, WA
Click here to add this to my saved trials
Using Virtual Reality (VR) Models for Preoperative Planning
Using Virtual Reality (VR) Models for Preoperative Planning
Status: Enrolling
Updated:  12/31/1969
Swedish Medical Center
mi
from
Seattle, WA
Using Virtual Reality (VR) Models for Preoperative Planning
Using Virtual Reality (VR) Models for Preoperative Planning
Status: Enrolling
Updated: 12/31/1969
Swedish Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Vinorelbine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Treatment and Liver Dysfunction
Pilot Pharmacokinetic Study of Dose Adjustment of Vinorelbine in Patients With Varying Degree of Liver Dysfunction
Status: Enrolling
Updated:  12/31/1969
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
Vinorelbine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Treatment and Liver Dysfunction
Pilot Pharmacokinetic Study of Dose Adjustment of Vinorelbine in Patients With Varying Degree of Liver Dysfunction
Status: Enrolling
Updated: 12/31/1969
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Vinorelbine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Treatment and Liver Dysfunction
Pilot Pharmacokinetic Study of Dose Adjustment of Vinorelbine in Patients With Varying Degree of Liver Dysfunction
Status: Enrolling
Updated:  12/31/1969
City of Hope Medical Group Inc
mi
from
Pasadena, CA
Vinorelbine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Treatment and Liver Dysfunction
Pilot Pharmacokinetic Study of Dose Adjustment of Vinorelbine in Patients With Varying Degree of Liver Dysfunction
Status: Enrolling
Updated: 12/31/1969
City of Hope Medical Group Inc
mi
from
Pasadena, CA
Click here to add this to my saved trials
Effectiveness Study of a Computer-Based Colorectal Cancer Screening Decision Aid
Overcoming Literacy Barriers in Colorectal Cancer Screening
Status: Enrolling
Updated:  12/31/1969
Wake Forest University Baptist Medical Center; Downtown Health Plaza
mi
from
Winston-Salem, NC
Effectiveness Study of a Computer-Based Colorectal Cancer Screening Decision Aid
Overcoming Literacy Barriers in Colorectal Cancer Screening
Status: Enrolling
Updated: 12/31/1969
Wake Forest University Baptist Medical Center; Downtown Health Plaza
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Using Behavioral Economics to Achieve Improved Healthy Behavior Outcomes in Breast Cancer Survivors
Using Behavioral Economics to Achieve Improved Healthy Behavior Outcomes in Breast Cancer Survivors
Status: Enrolling
Updated:  12/31/1969
Texas Tech University Health Sciences Center
mi
from
Lubbock, TX
Using Behavioral Economics to Achieve Improved Healthy Behavior Outcomes in Breast Cancer Survivors
Using Behavioral Economics to Achieve Improved Healthy Behavior Outcomes in Breast Cancer Survivors
Status: Enrolling
Updated: 12/31/1969
Texas Tech University Health Sciences Center
mi
from
Lubbock, TX
Click here to add this to my saved trials
Pembrolizumab and Radiation Therapy in Treating Patients With Intermediate or High-Grade Soft Tissue Sarcoma
A Pilot Study of Pembrolizumab and Neoadjuvant Radiation for Large, High-Grade Soft Tissue Sarcomas
Status: Enrolling
Updated:  12/31/1969
Fred Hutch/University of Washington Cancer Consortium
mi
from
Seattle, WA
Pembrolizumab and Radiation Therapy in Treating Patients With Intermediate or High-Grade Soft Tissue Sarcoma
A Pilot Study of Pembrolizumab and Neoadjuvant Radiation for Large, High-Grade Soft Tissue Sarcomas
Status: Enrolling
Updated: 12/31/1969
Fred Hutch/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
Stereotactic Radiation Therapy in Treating Patients With Liver Metastases
A Phase I Dose Finding Pilot Study of Stereotactic Body Radiotherapy for the Treatment of Liver Metastasis
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic, Jacksonville
mi
from
Jacksonville, FL
Stereotactic Radiation Therapy in Treating Patients With Liver Metastases
A Phase I Dose Finding Pilot Study of Stereotactic Body Radiotherapy for the Treatment of Liver Metastasis
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic, Jacksonville
mi
from
Jacksonville, FL
Click here to add this to my saved trials